Parkinson's Disease Research

Parkinson's disease (PD) is a degenerative disease of the central nervous system that often impairs motor skills, speech, and other functions. Symptoms of the disease include resting tremor, bradykinesia and rigidity. The primary symptoms are the result of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Symptoms of the disease appear once 50-80% of dopamine neurons have died. Parkinson's disease is both chronic and progressive.

Parkinson's Disease Research Products Targets

Products for Parkinson's Disease Research - Page 63

  1. Cat.No. Product Name Information/Activity
  2. BCC5918 PPDA 684283-16-7 PPDA chemical structure
  3. BCC7309 PPPA 113190-92-4 PPPA chemical structure
  4. BCC6292 QNZ 46 QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively). QNZ 46 chemical structure
  5. BCC7129 Remacemide hydrochloride 111686-79-4 Remacemide hydrochloride chemical structure
  6. BCC7234 Ro 04-5595 hydrochloride 64047-73-0 Ro 04-5595 hydrochloride chemical structure
  7. BCC4159 Ro 25-6981 Maleate Ro 25-6981 Maleate is a potent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. Ro 25-6981 Maleate chemical structure
  8. BCC7619 Ro 61-8048 Ro 61-8048 is a potent and selective inhibitors of kynurenine hydroxylase with IC50 of 37 nM. Ro 61-8048 chemical structure
  9. BCC7655 Ro 8-4304 hydrochloride 1312991-77-7 Ro 8-4304 hydrochloride chemical structure
  10. BCC6992 SDZ 220-040 174575-40-7 SDZ 220-040 chemical structure
  11. BCC1939 SDZ 220-581 SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7. SDZ 220-581 chemical structure

Items 621 to 630 of 752 total